US Stock Futures Edge Lower Ahead Of GDP, Consumer Sentiment Data

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade. Data on GDP growth for the fourth quarter will be released at 8:30 a.m. ET, while the University of Michigan's consumer sentiment index for March will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average dipped 27.50 points to 17,575.50, while the Standard & Poor's 500 index futures fell 2.05 points to 2,046.45. Futures for the Nasdaq 100 index declined 2.15 points to 4,308.60.
A Peek Into Global Markets
European markets were mixed today, with the Spanish Ibex Index dropping 0.04%, STOXX Europe 600 Index rising 0.58% and German DAX 30 index gaining 0.47%. French CAC 40 Index climbed 0.55% and London's FTSE 100 Index fell 0.37%. In Asian markets, Japan's Nikkei Stock Average slipped 0.95%, Hong Kong's Hang Seng Index dropped 0.04%, China's Shanghai Composite Index rose 0.24% and India's BSE Sensex gained 1.06 points.
Broker Recommendation
Analysts at Pacific Crest downgraded
EMC CorporationEMC
from Outperform to Sector Perform and removed the price target of $30.00. EMC shares fell 1.57% to $25.43 in pre-market trading.
Breaking news
  • BlackBerry Ltd. BBRY posted a surprise profit for the fiscal fourth quarter, but the company's sales missed analysts' estimates. To read the full news, click here.
  • Biogen BIIB and AbbVie ABBV announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA™ (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). To read the full news, click here.
  • Shares of Finish Line Inc. FINL jumped over 8% in pre-market trading after the company reported better-than-expected results for the fiscal fourth quarter. To read the full news, click here.
  • Auspex Pharmaceuticals, Inc. ASPX today announced that data from the completed Phase 3 registration clinical trial evaluating the company's investigational new drug SD-809 (AustedoTM) in chorea associated with Huntington's disease has been accepted for presentation at the 67th American Academy of Neurology (AAN) Annual Meeting taking place April 18-25, 2015 in Washington, DC. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsPacific CrestUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...